Loading...
Widespread popular interest in using psychedelic agents to treat a host of psychiatric disorders leaves clinicians eager for trustworthy guidance. The American Psychiatric Association's Workgroup on Biomarkers and Novel Treatments has now conducted a systematic review of pertinent articles published from 2007 through June 2019.
From 1603 articles screened, investigators identified 14 well-designed clinical studies examining the use of LSD (2 studies), 3,4-methylenedioxymethamphetamine (MDMA; 3), psilocybin (7), and ayahuasca (2). Several psychiatric conditions were examined (post-traumatic stress disorder [PTSD], treatment-resistant depression, anxiety and depression associated with cancer and other life-threatening diseases, and substance u…